TY - JOUR
T1 - A snapshot of antimicrobial resistance in Mexico. Results from 47 centers from 20 states during a six-month period
AU - Garza-González, Elvira
AU - Morfín-Otero, Rayo
AU - Mendoza-Olazarán, Soraya
AU - Bocanegra-Ibarias, Paola
AU - Flores-Treviño, Samantha
AU - Rodríguez-Noriega, Eduardo
AU - Ponce-de-León, Alfredo
AU - Sanchez-Francia, Domingo
AU - Franco-Cendejas, Rafael
AU - Arroyo-Escalante, Sara
AU - Velázquez-Acosta, Consuelo
AU - Rojas-Larios, Fabián
AU - Quintanilla, Luis J
AU - Maldonado-Anicacio, Joyarit Y
AU - Martínez-Miranda, Rafael
AU - Ostos-Cantú, Heidy L
AU - Gomez-Choel, Abraham
AU - Jaime-Sanchez, Juan L
AU - Avilés-Benítez, Laura K
AU - Feliciano-Guzmán, José M
AU - Peña-López, Cynthia D
AU - Couoh-May, Carlos A
AU - Molina-Jaimes, Aaron
AU - Vázquez-Narvaez, Elda G
AU - Rincón-Zuno, Joaquín
AU - Rivera-Garay, Raúl
AU - Galindo-Espinoza, Aurelio
AU - Martínez-Ramirez, Andrés
AU - Mora, Javier P
AU - Corte-Rojas, Reyna E
AU - López-Ovilla, Ismelda
AU - Monroy-Colin, Víctor A
AU - Barajas-Magallón, Juan M
AU - Morales-De-la-Peña, Cecilia T
AU - Aguirre-Burciaga, Efrén
AU - Coronado-Ramírez, Mabel
AU - Rosales-García, Alina A
AU - Ayala-Tarín, María-de-J
AU - Sida-Rodríguez, Silvia
AU - Pérez-Vega, Bertha A
AU - Navarro-Rodríguez, América
AU - Juárez-Velázquez, Gloria E
AU - Cetina-Umaña, Carlos Miguel
AU - Mena-Ramírez, Juan P
AU - Canizales-Oviedo, Jorge
AU - Moreno-Méndez, Martha Irene
AU - Romero-Romero, Daniel
AU - Arévalo-Mejía, Alejandra
AU - Cobos-Canul, Dulce Isabel
AU - Aguilar-Orozco, Gilberto
AU - Silva-Sánchez, Jesús
AU - Camacho-Ortiz, Adrián
N1 - Funding Information:
The author(s) received no specific funding for this work. This collaborative study is the result of the enthusiastic work of the Network for the Research and Surveillance of Drug Resistance (Invifar for its acronym in Spanish). We wish to acknowledge other members of the INVIFAR group (S2 Table), which at present includes 68 centers from 27 out of 32 states of Mexico.
Publisher Copyright:
© 2019 Garza-González et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/3/26
Y1 - 2019/3/26
N2 - AIM: We aimed to assess the resistance rates of antimicrobial-resistant, in bacterial pathogens of epidemiological importance in 47 Mexican centers.MATERIAL AND METHODS: In this retrospective study, we included a stratified sample of 47 centers, covering 20 Mexican states. Selected isolates considered as potential causatives of disease collected over a 6-month period were included. Laboratories employed their usual methods to perform microbiological studies. The results were deposited into a database and analyzed with the WHONET 5.6 software.RESULTS: In this 6-month study, a total of 22,943 strains were included. Regarding Gram-negatives, carbapenem resistance was detected in ≤ 3% in Escherichia coli, 12.5% in Klebsiella sp. and Enterobacter sp., and up to 40% in Pseudomonas aeruginosa; in the latter, the resistance rate for piperacillin-tazobactam (TZP) was as high as 19.1%. In Acinetobacter sp., resistance rates for cefepime, ciprofloxacin, meropenem, and TZP were higher than 50%. Regarding Gram-positives, methicillin resistance in Staphylococcus aureus (MRSA) was as high as 21.4%, and vancomycin (VAN) resistance reached up to 21% in Enterococcus faecium. Acinetobacter sp. presented the highest multidrug resistance (53%) followed by Klebsiella sp. (22.6%) and E. coli (19.4%).CONCLUSION: The multidrug resistance of Acinetobacter sp., Klebsiella sp. and E. coli and the carbapenem resistance in specific groups of enterobacteria deserve special attention in Mexico. Vancomycin-resistant enterococci (VRE) and MRSA are common in our hospitals. Our results present valuable information for the implementation of measures to control drug resistance.
AB - AIM: We aimed to assess the resistance rates of antimicrobial-resistant, in bacterial pathogens of epidemiological importance in 47 Mexican centers.MATERIAL AND METHODS: In this retrospective study, we included a stratified sample of 47 centers, covering 20 Mexican states. Selected isolates considered as potential causatives of disease collected over a 6-month period were included. Laboratories employed their usual methods to perform microbiological studies. The results were deposited into a database and analyzed with the WHONET 5.6 software.RESULTS: In this 6-month study, a total of 22,943 strains were included. Regarding Gram-negatives, carbapenem resistance was detected in ≤ 3% in Escherichia coli, 12.5% in Klebsiella sp. and Enterobacter sp., and up to 40% in Pseudomonas aeruginosa; in the latter, the resistance rate for piperacillin-tazobactam (TZP) was as high as 19.1%. In Acinetobacter sp., resistance rates for cefepime, ciprofloxacin, meropenem, and TZP were higher than 50%. Regarding Gram-positives, methicillin resistance in Staphylococcus aureus (MRSA) was as high as 21.4%, and vancomycin (VAN) resistance reached up to 21% in Enterococcus faecium. Acinetobacter sp. presented the highest multidrug resistance (53%) followed by Klebsiella sp. (22.6%) and E. coli (19.4%).CONCLUSION: The multidrug resistance of Acinetobacter sp., Klebsiella sp. and E. coli and the carbapenem resistance in specific groups of enterobacteria deserve special attention in Mexico. Vancomycin-resistant enterococci (VRE) and MRSA are common in our hospitals. Our results present valuable information for the implementation of measures to control drug resistance.
UR - http://www.scopus.com/inward/record.url?scp=85063438969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063438969&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0209865
DO - 10.1371/journal.pone.0209865
M3 - Article
C2 - 30913243
VL - 14
SP - e0209865
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 3
M1 - e0209865
ER -